These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26535714)

  • 1. Expression of Ras-related protein 25 predicts chemotherapy resistance and prognosis in advanced non-small cell lung cancer.
    Ma YF; Yang B; Li J; Zhang T; Guo JT; Chen L; Li M; Chu J; Liang CY; Liu Y
    Genet Mol Res; 2015 Oct; 14(4):13998-4008. PubMed ID: 26535714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
    Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
    Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
    Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
    Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
    Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
    J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
    Chen Y; Zhou H; Yang S; Su D
    Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
    Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
    Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
    Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
    Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis.
    Zhang R; Li Y; Wang Z; Chen L; Dong X; Nie X
    Tumour Biol; 2015 Nov; 36(11):8585-92. PubMed ID: 26040768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion.
    Cai S; Ye Z; Wang X; Pan Y; Weng Y; Lao S; Wei H; Li L
    J Exp Clin Cancer Res; 2015 May; 34(1):48. PubMed ID: 25975262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
    Sui C; Meng F; Li Y; Jiang Y
    J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
    Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
    Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
    Ma Y; Li X; Cheng S; Wei W; Li Y
    Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer.
    Wang S; Pan H; Liu D; Mao N; Zuo C; Li L; Xie T; Huang D; Huang Y; Pan Q; Yang L; Wu J
    Int J Oncol; 2015 Feb; 46(2):809-17. PubMed ID: 25434755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.
    Li A; Niu FY; Han JF; Lou NN; Yang JJ; Zhang XC; Zhou Q; Xie Z; Su J; Zhao N; Huang Y; Wu YL
    Lung Cancer; 2015 Dec; 90(3):375-80. PubMed ID: 26791795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.